Sight Diagnostics

Sight Diagnostics is an Israeli healthtech company focused on developing computer vision and AI-based blood testing devices. The company developed the OLO device, a complete blood count (CBC) analyzer that uses digital microscopy and image-analysis algorithms to identify and count blood cells without requiring traditional centrifugation or chemical reagents.

The flagship product, OLO, is designed to perform a full CBC at the point of care within minutes. The technology works by imaging blood droplets and applying automated image processing to classify cell types. The platform targets hospitals, clinics, and field settings where access to a full laboratory is limited. OLO received FDA clearance for the US market, enabling clinical commercialization there.

Sight Diagnostics operates R&D activity in Israel, and its founders and core technical team are Israeli. Further details about office locations, employee counts in Israel or globally, or capital-raise specifics are not known to me with sufficient confidence to include here.